Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment.
暂无分享，去创建一个
Ryan D. Morin | W. Klapper | D. Scott | C. Burton | L. Sehn | G. Slack | C. Klein | R. Morin | Pedro Farinha | M. Oestergaard | M. Cragg | M. Martelli | M. Rose-Zerilli | M. Nowicka | M. Trněný | J. Strefford | C. Bolen | S. Beers | U. Vitolo | R. Foxall | M. Ashton-Key | C. Hargreaves | F. Mir | L. Hilton | Chern-Horng Lee | A. Knapp | M. Carter | C. Rushton | K. Potter